Puma Biotechnology Share Price (NASDAQ: PBYI)

$5.06

▲

-0.67

(-11.69%)

Live

Last updated on August 18, 2025 at 11:38 PM IST

$₹

Check the interactive Puma Biotechnology Stock chart to analyse performance

Puma Biotechnology stock performance

as on August 18, 2025 at 11:38 PM IST

Today's Low:$4.82
Today's High:$5.96
$5.06
4.74%
Downside
Day's Volatility :19.13%
Upside
15.1%
52 Weeks Low:$2.23
52 Weeks High:$5.81
$5.06
56.03%
Downside
52 Weeks Volatility :61.7%
Upside
12.89%

Puma Biotechnology Stock Returns

Period	Puma Biotechnology, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	60.06%	2.3%	0.0%
6 Months	99.65%	-5.8%	0.0%
1 Year	102.47%	-10.9%	0.0%
3 Years	87.87%	2.8%	-11.6%

Puma Biotechnology, Inc. Key Stats

Check Puma Biotechnology key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$5.73
Open	$5.31
Today's High	$5.96
Today's Low	$4.82
Market Capitalization	$288.6M
Today's Volume	$1.0M
52 Week High	$5.96
52 Week Low	$2.225
Revenue TTM	$238.1M
EBITDA	$57.3M
Earnings Per Share (EPS)	$0.99
PE Ratio	5.79
Profit Margin	20.35%
Quarterly Earnings Growth YOY	0.59%
Return On Equity TTM	63.24%

Stock Returns calculator for Puma Biotechnology Stock including INR - Dollar returns

The Puma Biotechnology stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Puma Biotechnology investment value today

Current value as on today

₹1,82,872

Returns

₹82,872

(+82.87%)

Returns from Puma Biotechnology Stock

₹78,799 (+78.8%)

Dollar Returns*

₹4,073 (+4.07%)

Indian investors sentiment towards Puma Biotechnology Stock

30%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Puma Biotechnology Stock from India on INDmoney has increased by 30% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Puma Biotechnology, Inc.

Name
Holdings %
Name
Holdings %
BlackRock Inc
7.71%
Vanguard Group Inc
7.43%
Acadian Asset Management LLC
4.02%
Renaissance Technologies Corp
3.67%
Millennium Management LLC
2.78%
American Century Companies Inc
2.69%

Analyst Recommendation on Puma Biotechnology Stock

Rating

Trend

Sell

12%Buy

37%Hold

50%Sell

Based on 8 Wall street analysts offering stock ratings for Puma Biotechnology(by analysts ranked 0 to 5 stars)

Puma Biotechnology Share Price Target

What analysts predicted

Downside of 40.71%

Target:

$3.00

Current:

$5.06

Puma Biotechnology share price target is $3.00, a slight Downside of 40.71% compared to current price of $5.06 as per analysts' prediction.

Puma Biotechnology Stock Insights

Price Movement
In the last 7 days, PBYI stock has moved up by 18.1%
Increasing Revenue
Revenue is up for the last 2 quarters, 46.00M → 52.43M (in $), with an average increase of 12.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 2.97M → 5.85M (in $), with an average increase of 49.2% per quarter
PBYI vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 100.9% return, outperforming this stock by 21.3%

Puma Biotechnology, Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$272.3M	↑ 8.49%
Net Income	$-75.6M	↓ 33.46%
Net Profit Margin	-27.76%	↑ 17.5%

	FY20	Y/Y Change
Revenue	$225.1M	↓ 17.33%
Net Income	$-60.0M	↓ 20.63%
Net Profit Margin	-26.65%	↑ 1.11%

	FY21	Y/Y Change
Revenue	$253.2M	↑ 12.48%
Net Income	$-29.1M	↓ 51.5%
Net Profit Margin	-11.49%	↑ 15.16%

	FY22	Y/Y Change
Revenue	$228.0M	↓ 9.95%
Net Income	$2.0K	↓ 100.01%
Net Profit Margin	0.0%	↑ 11.49%

	FY23	Y/Y Change
Revenue	$235.6M	↑ 3.35%
Net Income	$21.6M	↑ 1079450.0%
Net Profit Margin	9.16%	↑ 9.16%

	FY24	Y/Y Change
Revenue	$230.5M	↓ 2.19%
Net Income	$30.3M	↑ 40.23%
Net Profit Margin	13.14%	↑ 3.98%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$43.8M	↓ 39.36%
Net Income	$-4.8M	↓ 139.25%
Net Profit Margin	-11.0%	↓ 28.0%

	Q2 FY24	Q/Q Change
Revenue	$47.1M	↑ 7.58%
Net Income	$-4.5M	↓ 5.94%
Net Profit Margin	-9.62%	↑ 1.38%

	Q3 FY24	Q/Q Change
Revenue	$80.5M	↑ 71.06%
Net Income	$20.3M	↓ 548.6%
Net Profit Margin	25.23%	↑ 34.85%

	Q4 FY24	Q/Q Change
Revenue	$59.1M	↓ 26.65%
Net Income	$19.3M	↓ 4.98%
Net Profit Margin	32.68%	↑ 7.45%

	Q1 FY25	Q/Q Change
Revenue	$46.0M	↓ 22.12%
Net Income	$3.0M	↓ 84.59%
Net Profit Margin	6.46%	↓ 26.22%

	Q2 FY25	Q/Q Change
Revenue	$52.4M	↑ 13.97%
Net Income	$5.9M	↑ 96.87%
Net Profit Margin	11.17%	↑ 4.71%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$235.5M	↑ 8.83%

	FY20	Y/Y Change
Profit	$185.7M	↓ 21.15%

	FY21	Y/Y Change
Profit	$189.5M	↑ 2.05%

	FY22	Y/Y Change
Profit	$172.9M	↓ 8.76%

	FY23	Y/Y Change
Profit	$173.0M	↑ 0.03%

	FY24	Y/Y Change
Profit	$166.1M	↓ 3.98%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$33.0M	↓ 30.96%

	Q2 FY24	Q/Q Change
Profit	$36.4M	↑ 10.25%

	Q3 FY24	Q/Q Change
Profit	$51.4M	↑ 41.24%

	Q4 FY24	Q/Q Change
Profit	$45.2M	↓ 12.22%

	Q1 FY25	Q/Q Change
Profit	$35.5M	↓ 21.49%

	Q2 FY25	Q/Q Change
Profit	$40.1M	↑ 13.21%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$22.4M	↓ 192.95%
Investing Cash Flow	$5.2M	↓ 109.03%
Financing Cash Flow	$-67.1M	↓ 161.9%

	FY20	Y/Y Change
Operating Cash Flow	$800.0K	↓ 96.43%
Investing Cash Flow	$23.3M	↑ 348.08%
Financing Cash Flow	$100.0K	↓ 100.15%

	FY21	Y/Y Change
Operating Cash Flow	$20.7M	↑ 2487.5%
Investing Cash Flow	$-10.9M	↓ 146.78%
Financing Cash Flow	$-31.9M	↓ 32000.0%

	FY22	Y/Y Change
Operating Cash Flow	$-15.8M	↓ 176.33%
Investing Cash Flow	$7.1M	↓ 165.14%
Financing Cash Flow	$12.2M	↓ 138.24%

	FY23	Y/Y Change
Operating Cash Flow	$27.0M	↓ 270.94%
Investing Cash Flow	$-19.1M	↓ 369.37%
Financing Cash Flow	$2.4M	↓ 80.07%

	FY24	Y/Y Change
Operating Cash Flow	$38.9M	↑ 44.09%
Investing Cash Flow	$-20.4M	↑ 6.87%
Financing Cash Flow	$-33.8M	↓ 1492.27%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$11.2M	↑ 7.57%
Investing Cash Flow	$-19.1M	↑ 133.54%
Financing Cash Flow	$0.0	-

	Q2 FY24	Q/Q Change
Operating Cash Flow	$1.0M	↓ 90.87%
Investing Cash Flow	$703.0K	↓ 103.68%
Financing Cash Flow	$-11.3M	-

	Q3 FY24	Q/Q Change
Operating Cash Flow	$11.0M	↑ 974.78%
Investing Cash Flow	$259.0K	↓ 63.16%
Financing Cash Flow	$-11.2M	↓ 1.31%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$15.6M	↑ 41.39%
Investing Cash Flow	$-2.3M	↓ 995.75%
Financing Cash Flow	$-11.3M	↑ 1.32%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$3.6M	↓ 76.86%
Investing Cash Flow	$1.5M	↓ 165.99%
Financing Cash Flow	$-11.3M	↑ 0.01%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$14.1M	↑ 289.87%
Investing Cash Flow	$-11.2M	↓ 834.68%
Financing Cash Flow	$-11.2M	↓ 1.15%

Puma Biotechnology Technicals Summary

Sell

Neutral

Buy

Puma Biotechnology is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Puma Biotechnology, Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Puma Biotechnology, Inc.	68.04%	99.65%	102.47%	87.87%	-47.53%
Regeneron Pharmaceuticals, Inc.	6.39%	-14.65%	-51.51%	-6.14%	-7.82%
Beone Medicines Ltd	10.08%	34.96%	66.94%	83.8%	36.85%
Vertex Pharmaceuticals Incorporated	-14.33%	-15.0%	-19.52%	31.35%	45.44%
Alnylam Pharmaceuticals, Inc.	40.06%	79.56%	63.55%	107.86%	227.15%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Puma Biotechnology, Inc.	5.79	5.79	0.03	0.7	0.63	0.14	NA	2.1
Regeneron Pharmaceuticals, Inc.	14.62	14.62	1.19	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.33	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.94	27.94	0.58	18.04	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Puma Biotechnology, Inc.	Sell	$288.6M	-47.53%	5.79	20.35%
Regeneron Pharmaceuticals, Inc.	Buy	$61.5B	-7.82%	14.62	31.37%
Beone Medicines Ltd	NA	$38.8B	36.85%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.7B	45.44%	27.94	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$58.0B	227.15%	NA	-12.96%

About Puma Biotechnology, Inc.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Organization	Puma Biotechnology
Employees	172
CEO	Mr. Alan H. Auerbach
Industry	Health Technology

Key Management of Puma Biotechnology, Inc.

Name	Title
Mr. Alan H. Auerbach	Founder, Chairman, President, CEO & Secretary
Mr. Maximo F. Nougues	CFO & Principal Accounting Officer
Mr. Douglas Hunt B.Sc., FRAPS	Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer
Mr. Mariann Ohanesian	Senior Director of Investor Relations

Important FAQs about investing in PBYI Stock from India :

What is Puma Biotechnology share price today?

Puma Biotechnology share price today is $5.06 as on August 18, 2025 at 11:38 PM IST. Puma Biotechnology share today touched a day high of $5.96 and a low of $4.82.

What is the 52 week high and 52 week low for Puma Biotechnology share?

Puma Biotechnology share touched a 52 week high of $5.81 and a 52 week low of $2.23. Puma Biotechnology stock price today, August 18, 2025 at 11:38 PM IST is trending at $5.06, lower by 12.89% versus the 52 week high.

How to invest in Puma Biotechnology Stock (PBYI) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Puma Biotechnology on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Puma Biotechnology Shares that will get you 0.2964 shares as per Puma Biotechnology share price of $5.06 per share as on August 18, 2025 at 11:38 PM IST.

What is the minimum amount required to buy Puma Biotechnology Stock (PBYI) from India?

Indian investors can start investing in Puma Biotechnology (PBYI) shares with as little as ₹87.3775 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹873.77 in Puma Biotechnology stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Puma Biotechnology share’s latest price of $5.06 as on August 18, 2025 at 11:38 PM IST, you will get 1.9763 shares of Puma Biotechnology. Learn more about fractional shares .

What are the returns that Puma Biotechnology has given to Indian investors in the last 5 years?

Puma Biotechnology stock has given -47.53% share price returns and 16.91% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?